Month: February 2020

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

Written by Customer Service on February 27, 2020. Posted in Public Companies.

Positive Top-line Results Announced from Head-to-Head Phase 3 PEGASUS Trial of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)Completion of Enrollment in Phase 3 PRINCE Trial in Treatment-Naïve PNH Patients Expected in First Half of 2020Full Enrollment of Two Phase 3 Trials in Geographic Atrophy Expected in First Half of 2020Cash Position of $352.0 Million as of December 31, 2019. Follow-on Offering in January Raised Additional Gross Proceeds of $404.2 Million; $20.0 Million Milestone Payment also Received in January from SFJ PharmaceuticalsWALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced its fourth quarter and full year 2019 financial results and...

Freddie Mac Issues Monthly Volume Summary for January 2020

Written by Customer Service on February 27, 2020. Posted in Public Companies.

MCLEAN, Va., Feb. 27, 2020 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) announced today that it issued its Monthly Volume Summary for January 2020, which provides information on Freddie Mac’s mortgage-related portfolios, securities issuance, risk management, delinquencies, debt activities, and other investments.Freddie Mac makes home possible for millions of families and individuals by providing mortgage capital to lenders. Since our creation by Congress in 1970, we’ve made housing more accessible and affordable for homebuyers and renters in communities nationwide. We are building a better housing finance system for homebuyers, renters, lenders, and taxpayers. Learn more at FreddieMac.com, Twitter @FreddieMac, and Freddie Mac’s blog FreddieMac.com/blog.MEDIA CONTACT: Fred Solomon703-903-3861Frederick_Solomon@freddiemac.comINVESTOR...

Midas Gold Announces US$35 Million Private Placement

Written by Customer Service on February 27, 2020. Posted in Public Companies.

Funding to support the continued permitting and feasibility work on the Stibnite Gold Project, IdahoNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.VANCOUVER, British Columbia, Feb. 27, 2020 (GLOBE NEWSWIRE) — Midas Gold Corp. (MAX:TSX / MDRPF:OTCQX, “Midas Gold” or the “Company”) today announced that it has entered into funding agreements for gross proceeds of US$35 million to be used for funding continued work on the Stibnite Gold Project and for general working capital purposes. Midas Gold has signed a binding term sheet with Paulson & Co. Inc., on behalf of the several investment funds and accounts managed by it (“Paulson”), pursuant to which Paulson will purchase Canadian dollar denominated...

Capital City Bank Group, Inc. Announces Cash Dividend

Written by Customer Service on February 27, 2020. Posted in Dividend Reports And Estimates.

TALLAHASSEE, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) — The Board of Directors of Capital City Bank Group, Inc. (NASDAQ: CCBG) declared a quarterly cash dividend on its common stock of $.14 per share. It represents a 7.7% increase over the prior quarter of $.13. The dividend produces an annualized rate of $.56 per common share and is payable on March 23, 2020 to shareowners of record as of March 9, 2020. The annualized dividend yield is 2.02% based on a closing stock price of $27.73 on February 26, 2020.About Capital City Bank Group, Inc.Capital City Bank Group, Inc. (NASDAQ: CCBG) is one of the largest publicly traded financial holding companies headquartered in Florida and has approximately $3.1 billion in assets. We provide a full range of banking services, including traditional deposit and credit services, mortgage banking, asset...

Chicken Soup for the Soul Entertainment to Present at 3rd Annual D.A. Davidson Consumer Growth Conference

Written by Customer Service on February 27, 2020. Posted in Public Companies.

COS COB, Conn., Feb. 27, 2020 (GLOBE NEWSWIRE) — Chicken Soup for the Soul Entertainment, Inc. (Nasdaq: CSSE), a growing media company building online video-on-demand (“VOD”) networks that provide video content for all screens, today announced that management will attend the 3rd Annual D.A. Davidson Consumer Growth Conference in New York City on March 12, 2020.Management is scheduled to present on Thursday, March 12 at 1:15 p.m. ET and will conduct one-on-one and small group meetings throughout the day.ABOUT CHICKEN SOUP FOR THE SOUL ENTERTAINMENTChicken Soup for the Soul Entertainment, Inc. (Nasdaq: CSSE) is a growing media company building and acquiring streaming video-on-demand networks (VOD) that provide content for all screens. The company owns a majority stake in Crackle Plus, a joint venture with Sony Pictures Television,...

Optinose to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 5, 2020

Written by Customer Service on February 27, 2020. Posted in Public Companies.

YARDLEY, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the fourth quarter and year-end 2019, before market open on Thursday, March 5, 2020.Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. The call is scheduled to start at 7:30 a.m. Eastern Time on Thursday, March 5, 2020.To participate on the conference call, please dial (866) 916-4761 from the U.S. or +1 (409) 216-6496 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until Thursday, March 12, 2020 by dialing (855) 859-2056 from the...

Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

Written by Customer Service on February 27, 2020. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019, and provided business highlights.“2019 was an extraordinary year for Denali with significant progress across our portfolio in programs targeting Alzheimer’s, ALS and Hunter syndrome, as well as completing our first patient trial for a LRRK2 inhibitor in Parkinson’s disease,” said Ryan Watts, Ph.D., CEO. “We look forward to building on this momentum in 2020 with key milestones expected for multiple programs, including advancing our LRRK2 program into late stage...

Pennant Announces Agreement to Form Home Health Joint Venture

Written by Customer Service on February 27, 2020. Posted in Public Companies.

EAGLE, Idaho, Feb. 27, 2020 (GLOBE NEWSWIRE) — The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that a subsidiary of Cornerstone Healthcare, Inc., its home health and hospice portfolio company, has entered into an agreement to form a home health joint venture with Scripps Health, a leading nonprofit integrated health system based in San Diego, California. The finalization of the joint venture is subject to customary closing conditions and is expected to occur in the third quarter of 2020. Following the closing of the transaction, the joint venture will be managed by a Cornerstone affiliate and will provide home health services to patients throughout San Diego County and surrounding areas. As the parties begin the integration...

Atlantica Reports Full Year 2019 Financial Results

Written by Customer Service on February 27, 2020. Posted in Dividend Reports And Estimates.

Net profit attributable to the Company for the full year 2019 was $62.1 million, compared with $41.6 million in 2018.Further Adjusted EBITDA including unconsolidated affiliates1 reached $821.6 million in 2019, representing an increase of 3.2% on a comparable basis2 compared to 2018.Cash available for distribution (“CAFD”) was $190.3 million in 2019, meeting annual guidance.Quarterly dividend of $0.41 per share declared by the Board of Directors, representing an 11% increase compared with the same quarter of 2018.2020 CAFD guidance established at >10% growth3 vs 2019 CAFD.Strong pipeline of potential equity investment opportunities.February 27, 2020 – Atlantica Yield plc (NASDAQ: AY) (“Atlantica”), the sustainable infrastructure company that owns a diversified portfolio of contracted assets in the energy and environment sectors, reported...

Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Written by Customer Service on February 27, 2020. Posted in Earnings Releases And Operating Results.

Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseCurrent capital funds operations into 2021Conference call and webcast today at 4:30 p.m. ETSAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the fourth quarter and year ended December 31, 2019 and provided an update on its product pipeline and corporate activities. The company will host a conference call and webcast today at 4:30 p.m. ET to discuss recent highlights and financial results.“We have positioned Otonomy for a transformational year in 2020 with three clinical trial readouts including the Phase 3 trial of OTIVIDEX in Ménière’s disease, Phase 2 trial...

Month: February 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals